Welcome to the
Hepatitis B Foundation
Warnings for Hepatitis B Reactivation in Cancer Patients Welcomed by the AASLD
Dec 2 – The FDA announced the requirement of a Boxed Warning for the anti-cancer immunosuppressive drugs Arzerra (ofatumumab) and Rituxan (rituximab), and is specific to the risk of reactivating hepatitis B in patients who were previously infected with the virus. Read more.
Arrowhead Submits Phase 2a Application for Hep B RNAi Candidate
Dec 2 – After announcing promising new data, Arrowhead has submitted its application to begin a phase II-a trial of ARC-520. Researchers will look to determine the effect of one intravenous dose of ARC-520, in combination with the oral antiviral entecavir, on hepatitis B surface antigen reduction. Read more.
Vaccine Implant Could Eliminate Painful Booster Shots
Dec 2 – Scientists in Europe have devised a novel new system that might one day replace booster shots. Patients would swallow a pill to trigger the release of vaccine doses from a gel implant placed beneath the skin. Read more.
Hepatitis B Foundation's Student Research Program
Receives Support from Fulton Bank
Nov 20 – The Hepatitis B Foundation’s (HBF) High School Enrichment Program recently received a $10,000 donation from the Fulton Bank. Read more.
The Hep B Foundation’s Baruch S. Blumberg Institute Hosts the 13th Annual Regional Biotech Conference
Nov 15 – Company leaders gathered at the PA Biotechnology Center to discuss ways to get products to market faster, saving valuable time and money during the process. Read more.
Page last modified December 2, 2013